Past issues are only available to subscribers. If you are not a member, click here to join.

Issue 14 - Apr. 3, 2020
  • Guest Editorial

    Friending viral foes:

    The Zika story and (perhaps) lessons for COVID-19

    On a recent call with directors of cancer centers, NCI Director Ned Sharpless reminded us that quarantines present opportunities for scientists to think deeply.

  • Letter from the editor & publisher

    We are in this together

    As the leading independent source of news in oncology, The Cancer Letter has decided that it is our moral imperative to provide coverage of COVID-19 free of charge until this crisis is resolved.

  • Guest Editorial

    What cancer immunologists are doing about COVID-19

    It’s hard to fathom the number of scientific discoveries that are exploding from the COVID-19 disaster. Though there may be tumbleweeds on every street around the globe and impotent silence in the shuttered stores of every town, the scientists at the frontline of this epidemic are busier and more energized than they’ve been in a long time.

  • Conversation with The Cancer Letter

    A COVID-19 update from New York:

    “The only thing I hear at night now is the wail of ambulances”

    It’s a jump that’s hard to fathom:

    Two weeks ago, there were 600 detected COVID-19 cases in the state of New York. At this writing, there are over 100,000 confirmed cases, a 170-fold increase that has filled hospitals and depleted medical supplies at an unprecedented scale.

  • Conversation with The Cancer Letter

    As Italy’s COVID-19 incidence curve flattens, Curigliano sees lessons for the U.S.

    Social isolation and containment have begun to flatten the curve of COVID-19 cases in Italy, Giuseppe Curigliano said to The Cancer Letter.

  • COVID-19 Updates

    • AACR to Congress: Act on PPE, ventilator and testing shortages
    • Advocacy organizations: Stop threatening health care workers who speak out about lack of PPE
    • American College of Surgeons: Health care workers need PPE
    • CPRIT suspends first cycle of awards for FY21
    • Scott Gottlieb: A road map for navigating COVID-19 in the U.S.
    • CMS addresses surge of COVID-19 patients
    • COA thanks CMS for telehealth expansion
    • LLS, partners commit $4.5M for blood cancer patients impacted by COVID-19
    • PharmaMar submits phase II clinical trial of Aplidin treatment of COVID-19 to the Spanish Medicines Agency
    • Study: Patients with new-onset digestive symptoms after possible COVID-19 contact should be suspected for the illness
    • Convalescent plasma donations to be collected by Versiti Blood Centers to treat COVID-19 patients
    • Metastatic breast cancer patient tests negative for COVID-19
    • FAQs and Guidances
  • TCCL Logo

  • Trials & Tribulations

    COVID-19 and cancer: Ethical dilemmas in immune checkpoint blockade

    As oncologists, we are all too familiar with making treatment recommendations and advising on end-of-life care in the absence of robust data. In ethical conundrums, we rely on guidance from our colleagues in the field, institutions, and national/international leadership bodies.

  • Clinical Roundup

    • Keytruda significantly improves PFS as first-line treatment in colorectal cancer indication
    • Phase III cancer vaccine trial meets primary endpoint
    • Caris Life Sciences develops AI-powered predictor of chemotherapy sensitivity in MCC
  • Drugs & Targets

    • FDA approves Imfinzi for ES-SCLC
    • EMA grants positive opinion to Adcetris combination in lymphoma indication
  • NCI Trials

    NCI Trials for April 2020

    The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. 

Issue 13 - Mar. 27, 2020
Issue 12 - Mar. 20, 2020